loading
前日終値:
$44.05
開ける:
$44.05
24時間の取引高:
96,839
Relative Volume:
0.24
時価総額:
$2.79B
収益:
$87.56M
当期純損益:
$-167.47M
株価収益率:
-15.67
EPS:
-2.76
ネットキャッシュフロー:
$-148.20M
1週間 パフォーマンス:
-5.91%
1か月 パフォーマンス:
-7.16%
6か月 パフォーマンス:
+22.39%
1年 パフォーマンス:
+128.00%
1日の値動き範囲:
Value
$42.87
$44.80
1週間の範囲:
Value
$41.12
$45.45
52週間の値動き範囲:
Value
$18.89
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1195)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
184
Name
Twitter
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

KYMR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KYMR 43.23 2.79B 87.56M -167.47M -148.20M -2.76
VRTX 447.61 115.74B 10.63B -479.80M -1.35B 13.33
REGN 744.50 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 592.97 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.87 24.49B 3.30B -501.07M 1.03B 11.54

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
Nov 20, 2024

Stephens Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World

Nov 20, 2024
pulisher
Nov 18, 2024

Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Stephens - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

US Bancorp DE Sells 651 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Stephens & Co. Initiates Coverage of Kymera Therapeutics (KYMR) with Overweight Recommendation - MSN

Nov 18, 2024
pulisher
Nov 15, 2024

Kymera Therapeutics (NASDAQ:KYMR) Shares Down 6.7%Here's What Happened - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Avoro Capital Advisors LLC Expands Stake in Kymera Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Long Term Trading Analysis for (KYMR) - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Bolsters Stake in Kymera Therapeutics Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $51.21 Average Price Target from Analysts - Defense World

Nov 12, 2024
pulisher
Nov 10, 2024

Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $49.00 at Morgan Stanley - Defense World

Nov 10, 2024
pulisher
Nov 09, 2024

Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $51.21 - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Wellington Management Group LLP's Strategic Acquisition in Kymer - GuruFocus.com

Nov 08, 2024
pulisher
Nov 05, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 05, 2024
pulisher
Nov 05, 2024

Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Kymera Therapeutics to Present at 5 Major Healthcare Investor Conferences in November | KYMR Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Mirae Asset Global Investments Co. Ltd. Boosts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Nov 05, 2024
pulisher
Nov 04, 2024

UBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Immunology to take front seat at Kymera - The Pharma Letter

Nov 04, 2024
pulisher
Nov 04, 2024

Earnings call: Kymera Therapeutics advances in immunology and oncology By Investing.com - Investing.com Australia

Nov 04, 2024
pulisher
Nov 04, 2024

Earnings call: Kymera Therapeutics advances in immunology and oncology - Investing.com India

Nov 04, 2024
pulisher
Nov 04, 2024

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St

Nov 04, 2024
pulisher
Nov 04, 2024

Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

FY2024 Earnings Estimate for KYMR Issued By Leerink Partnrs - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

Leerink Partnrs Issues Optimistic Estimate for KYMR Earnings - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World

Nov 03, 2024
pulisher
Nov 02, 2024

(KYMR) Long Term Investment Analysis - Stock Traders Daily

Nov 02, 2024
pulisher
Nov 02, 2024

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Guggenheim Increases Kymera Therapeutics (NASDAQ:KYMR) Price Target to $52.00 - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

The Latest Analyst Ratings For Kymera Therapeutics - Benzinga

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics (NASDAQ:KYMR) Receives "Buy" Rating from Truist Financial - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK

Nov 01, 2024
pulisher
Nov 01, 2024

B.Riley boosts Kymera stock target amid cautious optimism for STAT6 degrader - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics stock target lifted by Stifel, buy rating on oncology pivot - Investing.com UK

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Kymera Therapeutics (NASDAQ:KYMR) Shares Gap DownWhat's Next? - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Kymera Therapeutics (KYMR) Q3 2024 Earnings: EPS Misses at -$0.8 - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To K - GuruFocus.com

Oct 31, 2024
pulisher
Oct 30, 2024

Preview: Kymera Therapeutics's Earnings - Benzinga

Oct 30, 2024
pulisher
Oct 30, 2024

Insights Ahead: Kymera Therapeutics's Quarterly Earnings - Benzinga

Oct 30, 2024
pulisher
Oct 24, 2024

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN

Oct 24, 2024
pulisher
Oct 24, 2024

Kymera Therapeutics (KYMR) Scheduled to Post Earnings on Thursday - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases - StockTitan

Oct 24, 2024
pulisher
Oct 23, 2024

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 - ForexTV.com

Oct 23, 2024
pulisher
Oct 23, 2024

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium - The Manila Times

Oct 23, 2024
pulisher
Oct 17, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World

Oct 17, 2024
pulisher
Oct 16, 2024

Kymera Therapeutics (NASDAQ:KYMR) Trading 6.8% HigherStill a Buy? - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decline in Short Interest - MarketBeat

Oct 16, 2024

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):